• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Ocular Therapeutix Inc.

    12/28/23 4:17:19 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OCUL alert in real time by email
    SC 13G 1 tm2332531d2_sc13g.htm SC 13G

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

    Ocular Therapeutix, Inc.

     

    (Name of Issuer)

     

    Common Stock, $0.0001 par value per share

     

    (Title of Class of Securities)

     

    67576A 10 0

     

    (CUSIP Number)

     

    December 18, 2023

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨

    x

    ¨

    Rule 13d-1(b)

    Rule 13d-1(c)

    Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 67576A 10 0 Page 2 of 17

     

    1.

    Names of Reporting Persons

    Venrock Healthcare Capital Partners III, L.P.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x (1)  (b) ¨

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    7,775,760 (2)

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    7,775,760 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    7,775,760 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    6.8% (3)

    12.

    Type of Reporting Person (See Instructions)

    PN

           

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.

     

    (2)Consists of (i) 800,447 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 80,046 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 6,895,267 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon 114,832,114 shares of Common Stock outstanding as of December 18, 2023 upon the closing of the Issuer’s public offering, as reported in the prospectus supplement dated December 13, 2023 filed by the Issuer with the Securities and Exchange Commission (the “SEC”) on December 14, 2023.

     

     

     

     

    CUSIP No. 67576A 10 0 Page 3 of 17

     

    1.

    Names of Reporting Persons

    VHCP Co-Investment Holdings III, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x (1)  (b) ¨

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    7,775,760 (2)

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    7,775,760 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    7,775,760 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    6.8% (3)

    12.

    Type of Reporting Person (See Instructions)

    OO

           

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.

     

    (2)Consists of (i) 800,447 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 80,046 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 6,895,267 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon 114,832,114 shares of Common Stock outstanding as of December 18, 2023 upon the closing of the Issuer’s public offering, as reported in the prospectus supplement dated December 13, 2023 filed by the Issuer with the SEC on December 14, 2023.

     

     

     

     

    CUSIP No. 67576A 10 0 Page 4 of 17

     

    1.

    Names of Reporting Persons

    Venrock Healthcare Capital Partners EG, L.P.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x (1)  (b) ¨

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    7,775,760 (2)

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    7,775,760 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    7,775,760 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    6.8% (3)

    12.

    Type of Reporting Person (See Instructions)

    PN

           

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.

     

    (2)Consists of (i) 800,447 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 80,046 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 6,895,267 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon 114,832,114 shares of Common Stock outstanding as of December 18, 2023 upon the closing of the Issuer’s public offering, as reported in the prospectus supplement dated December 13, 2023 filed by the Issuer with the SEC on December 14, 2023.

     

     

     

     

    CUSIP No. 67576A 10 0 Page 5 of 17

     

    1.

    Names of Reporting Persons

    VHCP Management III, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x (1)  (b) ¨

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    7,775,760 (2)

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    7,775,760 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    7,775,760 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    6.8% (3)

    12.

    Type of Reporting Person (See Instructions)

    OO

           

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.

     

    (2)Consists of (i) 800,447 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 80,046 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 6,895,267 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon 114,832,114 shares of Common Stock outstanding as of December 18, 2023 upon the closing of the Issuer’s public offering, as reported in the prospectus supplement dated December 13, 2023 filed by the Issuer with the SEC on December 14, 2023.

     

     

     

     

    CUSIP No. 67576A 10 0 Page 6 of 17

     

    1.

    Names of Reporting Persons

    VHCP Management EG, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x (1)  (b) ¨

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    7,775,760 (2)

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    7,775,760 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    7,775,760 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    6.8% (3)

    12.

    Type of Reporting Person (See Instructions)

    OO

           

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.

     

    (2)Consists of (i) 800,447 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 80,046 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 6,895,267 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon 114,832,114 shares of Common Stock outstanding as of December 18, 2023 upon the closing of the Issuer’s public offering, as reported in the prospectus supplement dated December 13, 2023 filed by the Issuer with the SEC on December 14, 2023.

     

     

     

     

    CUSIP No. 67576A 10 0 Page 7 of 17

     

    1.

    Names of Reporting Persons

    Shah, Nimish

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x (1)  (b) ¨

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    7,775,760 (2)

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    7,775,760 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    7,775,760 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    6.8% (3)

    12.

    Type of Reporting Person (See Instructions)

    IN

           

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.

     

    (2)Consists of (i) 800,447 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 80,046 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 6,895,267 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon 114,832,114 shares of Common Stock outstanding as of December 18, 2023 upon the closing of the Issuer’s public offering, as reported in the prospectus supplement dated December 13, 2023 filed by the Issuer with the SEC on December 14, 2023.

     

     

     

     

    CUSIP No. 67576A 10 0 Page 8 of 17

     

    1.

    Names of Reporting Persons

    Koh, Bong

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x (1)  (b) ¨

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    7,775,760 (2)

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    7,775,760 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    7,775,760 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    6.8% (3)

    12.

    Type of Reporting Person (See Instructions)

    IN

           

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.

     

    (2)Consists of (i) 800,447 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 80,046 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 6,895,267 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon 114,832,114 shares of Common Stock outstanding as of December 18, 2023 upon the closing of the Issuer’s public offering, as reported in the prospectus supplement dated December 13, 2023 filed by the Issuer with the SEC on December 14, 2023.

     

     

     

     

    CUSIP No. 67576A 10 0 Page 9 of 17

     

    Item 1.    
      (a)

    Name of Issuer

     

    Ocular Therapeutix, Inc.

         
      (b)

    Address of Issuer’s Principal Executive Offices

     

    24 Crosby Drive, Bedford, MA 01730

         
    Item 2.    
      (a)

    Name of Person Filing

     

    Venrock Healthcare Capital Partners III, L.P.

    VHCP Co-Investment Holdings III, LLC

    Venrock Healthcare Capital Partners EG, L.P.

    VHCP Management III, LLC

    VHCP Management EG, LLC

    Nimish Shah

    Bong Koh

         
      (b)

    Address of Principal Business Office or, if none, Residence

     

    New York Office:                        Palo Alto Office:

     

    7 Bryant Park                                3340 Hillview Avenue

    23rd Floor                                       Palo Alto, CA 94304

    New York, NY 10018

         
      (c)

    Citizenship

     

    All of the Venrock Entities were organized in Delaware. The individuals are both United States citizens.

     
      (d)

    Title of Class of Securities

     

    Common Stock, $0.0001 par value

         
      (e)

    CUSIP Number

     

    67576A 10 0

         
    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
       
      Not applicable

     

     

     

     

    CUSIP No. 67576A 10 0 Page 10 of 17

     

    Item 4. Ownership  
         
      (a) Amount beneficially owned:  
           
          Venrock Healthcare Capital Partners III, L.P. 7,775,760  (1)  
          VHCP Co-Investment Holdings III, LLC 7,775,760  (1)  
          Venrock Healthcare Capital Partners EG, L.P. 7,775,760  (1)  
          VHCP Management III, LLC 7,775,760  (1)  
          VHCP Management EG, LLC 7,775,760  (1)  
          Nimish Shah 7,775,760  (1)  
          Bong Koh 7,775,760  (1)  
             
      (b) Percent of class:  
           
          Venrock Healthcare Capital Partners III, L.P. 6.8%  (2)  
          VHCP Co-Investment Holdings III, LLC 6.8%  (2)  
          Venrock Healthcare Capital Partners EG, L.P. 6.8%  (2)  
          VHCP Management III, LLC 6.8%  (2)  
          VHCP Management EG, LLC 6.8%  (2)  
          Nimish Shah 6.8%  (2)  
          Bong Koh 6.8%  (2)  
             
      (c) Number of shares as to which the person has:  
           
        (i) Sole power to vote or to direct the vote:  
           
          Venrock Healthcare Capital Partners III, L.P. 0  
          VHCP Co-Investment Holdings III, LLC 0  
          Venrock Healthcare Capital Partners EG, L.P. 0  
          VHCP Management III, LLC 0  
          VHCP Management EG, LLC 0  
          Nimish Shah 0  
          Bong Koh 0  
             
        (ii) Shared power to vote or to direct the vote:  
           
          Venrock Healthcare Capital Partners III, L.P. 7,775,760  (1)  
          VHCP Co-Investment Holdings III, LLC 7,775,760  (1)  
          Venrock Healthcare Capital Partners EG, L.P. 7,775,760  (1)  
          VHCP Management III, LLC 7,775,760  (1)  
          VHCP Management EG, LLC 7,775,760  (1)  
          Nimish Shah 7,775,760  (1)  
          Bong Koh 7,775,760  (1)  

     

     

     

     

    CUSIP No. 67576A 10 0 Page 11 of 17

     

        (iii) Sole power to dispose or to direct the disposition of:  
           
          Venrock Healthcare Capital Partners III, L.P. 0  
          VHCP Co-Investment Holdings III, LLC 0  
          Venrock Healthcare Capital Partners EG, L.P. 0  
          VHCP Management III, LLC 0  
          VHCP Management EG, LLC 0  
          Nimish Shah 0  
          Bong Koh 0  
             
        (iv) Shared power to dispose or to direct the disposition of:  
           
          Venrock Healthcare Capital Partners III, L.P. 7,775,760  (1)  
          VHCP Co-Investment Holdings III, LLC 7,775,760  (1)  
          Venrock Healthcare Capital Partners EG, L.P. 7,775,760  (1)  
          VHCP Management III, LLC 7,775,760  (1)  
          VHCP Management EG, LLC 7,775,760  (1)  
          Nimish Shah 7,775,760  (1)  
          Bong Koh 7,775,760  (1)  

     

      (1)Consists of (i) 800,447 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 80,046 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 6,895,267 shares held by Venrock Healthcare Capital Partners EG, L.P. VHCP Management III, LLC is the general partner of Venrock Healthcare Capital Partners III, L.P. and the manager of VHCP Co-Investment Holdings III, LLC. VHCP Management EG, LLC is the general partner of Venrock Healthcare Capital Partners EG, L.P. Messrs. Shah and Koh are the voting members of VHCP Management III, LLC and VHCP Management EG, LLC.

     

      (2)This percentage is calculated based upon 114,832,114 shares of Common Stock outstanding as of December 18, 2023 upon the closing of the Issuer’s public offering, as reported in the prospectus supplement dated December 13, 2023 filed by the Issuer with the SEC on December 14, 2023.

     

    Item 5. Ownership of Five Percent or Less of a Class
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following   ¨
     
    Item 6. Ownership of More than Five Percent on Behalf of Another Person
       
      Not applicable
     
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person
       
      Not applicable

     

     

     

     

    CUSIP No. 67576A 10 0 Page 12 of 17

     

    Item 8. Identification and Classification of Members of the Group
       
      Not applicable
     
    Item 9. Notice of Dissolution of Group
       
      Not applicable
     
    Item 10. Certification
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.

     

     

     

     

    CUSIP No. 67576A 10 0 Page 13 of 17

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: December 28, 2023

     

    Venrock Healthcare Capital Partners III, L.P.   Venrock Healthcare Capital Partners EG, L.P.
         
    By: VHCP Management III, LLC   By: VHCP Management EG, LLC
    Its: General Partner   Its: General Partner
         
    By: /s/ Sherman G. Souther   By: /s/ Sherman G. Souther
      Name: Sherman G. Souther     Name: Sherman G. Souther
      Its: Authorized Signatory     Its: Authorized Signatory
         
    VHCP Co-Investment Holdings III, LLC    
         
    By: VHCP Management III, LLC    
    Its: Manager    
         
    By: /s/ Sherman G. Souther    
      Name: Sherman G. Souther    
      Its: Authorized Signatory    
         
    VHCP Management III, LLC   VHCP Management EG, LLC
         
    By: /s/ Sherman G. Souther   By: /s/ Sherman G. Souther
      Name: Sherman G. Souther     Name: Sherman G. Souther
      Its: Authorized Signatory     Its: Authorized Signatory
         
    Nimish Shah    
         
    /s/ Sherman G. Souther    
    Sherman G. Souther, Attorney-in-fact      
         
    Bong Koh    
         
    /s/ Sherman G. Souther    
    Sherman G. Souther, Attorney-in-fact    

     

     

     

     

    CUSIP No. 67576A 10 0 Page 14 of 17

     

    EXHIBITS

     

    A: Joint Filing Agreement
       
    B: Power of Attorney for Nimish Shah
       
    C: Power of Attorney for Bong Koh

     

     

     

     

    CUSIP No. 67576A 10 0 Page 15 of 17

     

    EXHIBIT A

     

    JOINT FILING AGREEMENT

     

    In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of Ocular Therapeutix, Inc. and further agree that this agreement be included as an exhibit to such filing. Each party to the agreement expressly authorizes each other party to file on its behalf any and all amendments to such statement. Each party to this agreement agrees that this joint filing agreement may be signed in counterparts.

     

    In evidence whereof, the undersigned have caused this Agreement to be executed on their behalf this 28th day of December, 2023.

     

    Venrock Healthcare Capital Partners III, L.P.   Venrock Healthcare Capital Partners EG, L.P.
         
    By: VHCP Management III, LLC   By: VHCP Management EG, LLC
    Its: General Partner   Its: General Partner
         
    By: /s/ Sherman G. Souther   By: /s/ Sherman G. Souther
      Name: Sherman G. Souther     Name: Sherman G. Souther
      Its: Authorized Signatory     Its: Authorized Signatory
         
    VHCP Co-Investment Holdings III, LLC    
         
    By: VHCP Management III, LLC    
    Its: Manager    
         
    By: /s/ Sherman G. Souther    
      Name: Sherman G. Souther    
      Its: Authorized Signatory    
         
    VHCP Management III, LLC   VHCP Management EG, LLC
         
    By: /s/ Sherman G. Souther   By: /s/ Sherman G. Souther
      Name: Sherman G. Souther     Name: Sherman G. Souther
      Its: Authorized Signatory     Its: Authorized Signatory
         
    Nimish Shah    
         
    /s/ Sherman G. Souther    
    Sherman G. Souther, Attorney-in-fact    
         
    Bong Koh    
         
    /s/ Sherman G. Souther    
    Sherman G. Souther, Attorney-in-fact    

     

     

     

     

    CUSIP No. 67576A 10 0 Page 16 of 17

     

    EXHIBIT B

     

    POWER OF ATTORNEY FOR NIMISH SHAH

     

    KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints each of David L. Stepp, Sherman G. Souther and Lisa D. Harris signing individually, the undersigned’s true and lawful attorney-in fact and agent to:

     

    (i)prepare execute and file, for and on behalf of the undersigned, any and all documents and filings that are required or advisable to be made with the United States Securities and Exchange Commission, any stock exchange or similar authority, under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules and regulations promulgated thereunder, including without limitation (a) any Joint Filing Agreement under Rule 13d-1(k) of the Exchange Act (or any successor provision thereunder), Schedule 13D and Schedule 13G (or any successor schedules or forms adopted under the Exchange Act ) and any amendments thereto in accordance with Section 13 of the Exchange Act and the rules thereunder, and (b) Forms 3, 4 and 5 and any amendments thereto in accordance with Section 16(a) of the Exchange Act and the rules thereunder; and

     

    (ii)take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

     

    The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of undersigned, is not assuming, nor is Venrock assuming, any of the undersigned’s responsibilities to comply with the Exchange Act, including without limitation Sections 13 and 16 of the Exchange Act.

     

    This power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file any form or document with respect to the undersigned’s holdings of and transactions in securities issued by a company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorney-in-fact, or (c) until such attorney-in-fact shall no longer be employed by VR Management, LLC (or its successor).

     

    IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 28th day of December, 2023.

     

    /s/ Nimish Shah  

     

     

     

     

    CUSIP No. 67576A 10 0 Page 17 of 17

     

    EXHIBIT C

     

    POWER OF ATTORNEY FOR BONG KOH

     

    KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints each of David L. Stepp, Sherman G. Souther and Lisa D. Harris signing individually, the undersigned’s true and lawful attorney-in fact and agent to:

     

    (i)prepare execute and file, for and on behalf of the undersigned, any and all documents and filings that are required or advisable to be made with the United States Securities and Exchange Commission, any stock exchange or similar authority, under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules and regulations promulgated thereunder, including without limitation (a) any Joint Filing Agreement under Rule 13d-1(k) of the Exchange Act (or any successor provision thereunder), Schedule 13D and Schedule 13G (or any successor schedules or forms adopted under the Exchange Act ) and any amendments thereto in accordance with Section 13 of the Exchange Act and the rules thereunder, and (b) Forms 3, 4 and 5 and any amendments thereto in accordance with Section 16(a) of the Exchange Act and the rules thereunder; and

     

    (ii)take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

     

    The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of undersigned, is not assuming, nor is Venrock assuming, any of the undersigned’s responsibilities to comply with the Exchange Act, including without limitation Sections 13 and 16 of the Exchange Act.

     

    This power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file any form or document with respect to the undersigned’s holdings of and transactions in securities issued by a company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorney-in-fact, or (c) until such attorney-in-fact shall no longer be employed by VR Management, LLC (or its successor).

     

    IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 28th day of December, 2023.

     

    /s/ Bong Koh  

     

     

     

    Get the next $OCUL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OCUL

    DatePrice TargetRatingAnalyst
    4/8/2025Outperform
    William Blair
    3/18/2025$17.00Outperform
    RBC Capital Mkts
    3/11/2025$15.00Buy
    Needham
    10/16/2024Sector Outperform
    Scotiabank
    6/20/2024$7.00 → $11.00Hold → Buy
    TD Cowen
    5/31/2024$15.00Overweight
    Piper Sandler
    2/9/2024$15.00Buy
    BofA Securities
    4/21/2023$18.00Outperform
    Robert W. Baird
    More analyst ratings

    $OCUL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Ocular Therapeutix™ to Participate in Upcoming Investor Conferences

      BEDFORD, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), a fully-integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming investor conferences in the second half of May 2025. 2025 RBC Capital Markets Global Healthcare Conference, May 20, 2025 Fireside Chat Date: Tuesday, May 20, 2025Fireside Chat Time: 2:35PM ETPresenter: Pravin U. Dugel, MD, Executive Chairman, President and CEOLocation: New York, NY HC Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ, May 20, 2025Fireside Chat Date: Tuesday, May 20, 2025Fireside Chat Time: 4:30PM ETPresenter: Pravin

      5/14/25 7:00:00 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ocular Therapeutix™ Reports First Quarter 2025 Results and Business Highlights

      AXPAXLI™ SOL trials for wet AMD progressing rapidly following recent updates to accelerate and enhance the registrational program Following positive FDA feedback for potential AXPAXLI NPDR registrational trial, Ocular is actively planning next steps in NPDR and DME SOL-1 retention remains exceptional as trial is on track for 1Q 2026 topline data readout SOL-R continues to have strong enrollment through streamlined, accelerated execution Cash balance of $349.7M as of March 31, 2025, with expected runway through topline data for SOL-1 and SOL-R and into 2028 BEDFORD, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), a fully-integrated biopharma

      5/5/25 7:00:00 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ocular Therapeutix™ to Participate in Upcoming Investor and Scientific Conferences

      BEDFORD, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), a biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming investor and scientific conferences in the first half of May 2025. Upcoming Investor Conferences Citizens JMP Life Sciences Conference 2025:Fireside Chat Date: Wednesday, May 7, 2025Fireside Chat Time: 9:00 AM ETPresenter: Pravin U. Dugel, MD, Executive Chairman, President and CEOLocation: New York, NY Bank of America 2025 Global Healthcare Conference:Fireside Chat Date: Tuesday, May 13, 2025Fireside Chat Time: 9:20 AM PTPresenter: Pravin U. Dugel, MD, Executive C

      4/29/25 7:00:00 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OCUL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Lindstrom Richard L Md bought $69,600 worth of shares (10,000 units at $6.96), increasing direct ownership by 6% to 172,704 units (SEC Form 4)

      4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

      5/12/25 8:50:46 PM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Dugel Pravin sold $147,533 worth of shares (21,475 units at $6.87), decreasing direct ownership by 0.61% to 3,520,318 units (SEC Form 4)

      4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

      2/26/25 6:27:13 PM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Scientific Officer Heier Jeffrey S. sold $21,029 worth of shares (3,061 units at $6.87), decreasing direct ownership by 1% to 265,998 units (SEC Form 4)

      4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

      2/26/25 6:25:32 PM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OCUL
    SEC Filings

    See more
    • SEC Form 10-Q filed by Ocular Therapeutix Inc.

      10-Q - OCULAR THERAPEUTIX, INC (0001393434) (Filer)

      5/5/25 7:47:55 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ocular Therapeutix Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - OCULAR THERAPEUTIX, INC (0001393434) (Filer)

      5/5/25 7:06:05 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Ocular Therapeutix Inc.

      DEFA14A - OCULAR THERAPEUTIX, INC (0001393434) (Filer)

      4/29/25 5:01:27 PM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OCUL
    Financials

    Live finance-specific insights

    See more
    • Ocular Therapeutix™ to Report First Quarter 2025 Financial Results on May 5, 2025

      BEDFORD, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), a biopharmaceutical company committed to redefining the retina experience, today announced that it plans to issue a press release regarding first quarter 2025 financial results on Monday, May 5, 2025 at 7:00 AM Eastern Time. The Company will not be hosting a first quarter 2025 conference call and plans to resume quarterly earnings calls for its second quarter 2025 financial results. Information about the Company's quarterly results, conference calls, webcasts and other investor information are posted on the Company's website. About Ocular Therapeutix, Inc.Ocular Therapeutix, Inc.

      4/28/25 7:00:00 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2024 Results and Business Highlights

      Announces several updates to enhance and accelerate AXPAXLI registrational program in wet AMD, potentially supporting label flexibility of 6-12 months to showcase expected best-in-class durability FDA approves Amendment to SOL-1 Special Protocol Agreement (SPA) to include AXPAXLI re-dosing at Weeks 52 and 76 SOL-1 trial Week 36 primary endpoint data now expected in 1Q 2026 due to requirement for masking until Week 52 to allow for re-dosing Inclusion of re-dosing in SOL-1, along with exceptional retention seen to date in the study, paves way for reduction of SOL-R trial size to 555 subjects (previously 825), potentially accelerating registration timelines Additional updates provided on SO

      3/3/25 7:00:00 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ocular Therapeutix™ to Report Fourth Quarter and Full Year 2024 Results on March 3, 2025

      BEDFORD, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), a biopharmaceutical company committed to redefining the retina experience, today announced that it plans to host a conference call and webcast on Monday, March 3, 2025, at 8:00 AM ET to discuss recent business progress and financial results for the fourth quarter and full year ended December 31, 2024. Conference Call and Webcast Information: Date: Monday, March 3, 2025, at 8:00 AM ET Participant Dial-In (U.S.): 1 (877) 407-9039 Participant Dial-in (International): 1 (201) 689-8470 Conference ID: 13750940 Webcast Access: Please click here The live and archived webcast can also be acce

      2/24/25 7:00:00 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OCUL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Lindstrom Richard L Md bought $69,600 worth of shares (10,000 units at $6.96), increasing direct ownership by 6% to 172,704 units (SEC Form 4)

      4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

      5/12/25 8:50:46 PM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Summer Road Llc bought $7,000,000 worth of shares (930,851 units at $7.52) (SEC Form 4)

      4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

      2/27/24 4:43:51 PM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Summer Road Llc bought $4,999,998 worth of shares (1,538,461 units at $3.25) (SEC Form 4)

      4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

      12/18/23 4:52:33 PM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OCUL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • William Blair initiated coverage on Ocular Therapeutix

      William Blair initiated coverage of Ocular Therapeutix with a rating of Outperform

      4/8/25 9:29:59 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RBC Capital Mkts initiated coverage on Ocular Therapeutix with a new price target

      RBC Capital Mkts initiated coverage of Ocular Therapeutix with a rating of Outperform and set a new price target of $17.00

      3/18/25 7:53:57 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Needham initiated coverage on Ocular Therapeutix with a new price target

      Needham initiated coverage of Ocular Therapeutix with a rating of Buy and set a new price target of $15.00

      3/11/25 7:42:03 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OCUL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Ocular Therapeutix Inc.

      SC 13G/A - OCULAR THERAPEUTIX, INC (0001393434) (Subject)

      11/14/24 5:49:38 PM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Ocular Therapeutix Inc.

      SC 13G - OCULAR THERAPEUTIX, INC (0001393434) (Subject)

      11/14/24 9:37:26 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Ocular Therapeutix Inc.

      SC 13G/A - OCULAR THERAPEUTIX, INC (0001393434) (Subject)

      11/12/24 4:49:23 PM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OCUL
    Leadership Updates

    Live Leadership Updates

    See more
    • Ocular Therapeutix® to Host Investor Day on June 13, 2024

      Company to highlight corporate strategy, clinical data, and development plans for AXPAXLI™ in wet AMD and NPDR Event to feature prominent retinal disease experts Baruch D. Kuppermann, MD, PhD (University of California, Irvine) and Dilsher S. Dhoot, MD (California Retina Consultants) In-person event with virtual access to take place on June 13, 2024, at 2:00 PM ET BEDFORD, Mass., June 05, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular", the "Company"))), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD

      6/5/24 7:30:00 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ocular Therapeutix™ Reports First Quarter 2024 Results

      Recent Leadership Appointments Put Ocular on Track to Become a Leader in Retinal Care Site Activation and Patient Enrollment for AXPAXLI™ SOL-1 Phase 3 wet AMD Trial Progressing with First Subjects Randomized in April 2024 Cash Expected to Support Operations Into 2028, Based on $482.9M March 31, 2024, Cash Balance June 13, 2024, Investor Day to Outline Updated Corporate Strategy BEDFORD, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular", the "Company"))), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degenerati

      5/7/24 4:05:00 PM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders

      Nadia K. Waheed, MD, MPH, Appointed Chief Medical Officer; Peter K. Kaiser, MD, to Become Chief Development Officer; Andrea Gibson, PhD, Named Vice President, Medical Collaborations; and Namrata Saroj, OD, to Become Development Strategy Consultant Dr. Waheed's strong industry track record as a CMO and broad expertise in wet AMD and diabetic retinopathy support advancing the Phase 3 AXPAXLI™ program Dr. Kaiser's vast leadership experience in numerous pivotal trials of approved wet AMD products enhances Ocular's transition to a leading retina care company Dr. Gibson and Dr. Saroj bring deep experience in clinical trial execution through their joint involvement in the development and commerc

      4/16/24 7:00:00 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care